21 September 2012 -- Universal Biosensors (ASX.UBI) has strengthened its partnership with Siemens Healthcare Diagnostics, announcing today it has signed a long term supply and manufacturing agreement which will see UBI become the exclusive manufacturer of three test strips currently being jointly developed for the point-of-care (POC) coagulation testing market.
Universal Biosensors is developing with Siemens, a range of products for the POC coagulation testing market. The signing of the supply and manufacturing agreement represents an important milestone for Universal Biosensors in the lead up to the launch of the first product in this range, a PT-INR testing system used to monitor the application of the anti-coagulant therapy Warfarin, which is expected to be commercially available in 2013.
The supply and manufacturing agreement means that UBI will be the exclusive manufacturer of the three test strips currently in development. The strips will be manufactured at the company’s existing plant in Rowville, Victoria. In turn, Siemens will register, market, and sell the products globally.
Apart from the ongoing R&D milestone payments to be received from Siemens, Universal Biosensors will generate a return on its R&D investment in coagulation testing via its gross margin earned on the manufacture and supply of test strips to Siemens. In addition, consistent with the collaboration philosophy, Universal Biosensors will share in incremental profits generated by Siemens on sales of these products that exceed their current forecasts by a specified amount.
UBI CEO Paul Wright said, “The signing of this Supply Agreement is a major step forward in our relationship with Siemens and towards our shared vision for bringing a range of novel handheld analysers to the POC coagulation testing market. Universal Biosensors will leverage its existing infrastructure to offer world-class manufacturing support to Siemens and create a new and important long term earnings stream for our business.”
Point-of-care coagulation testing is estimated to be worth over US$1billion annually and is growing at over 10% per year as a result of the increased use of anti-coagulant therapies such as warfarin and heparin, used to prevent the development of blood clots. Use of these medications needs to be closely monitored, and currently requires frequent blood tests.
The systems being developed by Universal Biosensors and Siemens will deliver laboratory-quality results at the point-of-care in response to growing demand for near-patient testing solutions, including those that deliver time-critical coagulation data.
An SEC Form 8-K which summarises the material terms of the supply and manufacturing agreement will be filed with the SEC overnight (during SEC business hours) and released to ASX on Monday 24 September 2012. A redacted form of the supply and manufacturing agreement will be filed with UBI’s next quarterly Form 10-Q SEC filing.
Mr Paul Wright: 03 9213 9000
About Universal Biosensors
For additional information in relation to Universal Biosensors, refer to
Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.
The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.